science wire



Results 1251 - 1300 of 1581.

Health - Pharmacology - 04.09.2013
Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013
Robust efficacy of once-daily Ultibro Breezhaler (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro LABA+LAMA combination for the treatment of COPD patients , , Once-daily Seebri Breezhaler (glycopyrronium) efficacy data strengthened by new analyses from the SPARK study on exacerbations and lung function in severe and very severe COPD patients , Basel, September 4,

Pharmacology - Health - 03.09.2013
Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given

Health - Pharmacology - 02.09.2013
Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2]
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress , If approved, RLX030 has the potential to be the first treatment breakthrough for AHF patients in 20 years , Basel, September 2, 2013 - Results from a new analysis of the Phase III RELAX-AHF study published today in the European Heart Journal and presented as a late breaker at the European Society of C

Pharmacology - Health - 20.08.2013
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
BYM338 is the third Novartis investigational treatment this year to receive a breakthrough therapy designation by the FDA, highlighting Novartis' leadership in the industry in breakthrough therapy designations Basel, August 20, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM).

Health - Pharmacology - 15.08.2013
Novartis vaccine Bexsero approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis
Australia approval marks a key step in expanding access to the first and only broad coverage vaccine against MenB disease , ; Bexsero was granted European licensure this past January MenB disease is

Health - Pharmacology - 08.08.2013
Novartis first company accredited with global "CEO Cancer Gold Standard" for outstanding efforts in cancer prevention and treatment
The non-profit CEO Roundtable on Cancer has recognized the programs Novartis has to support associates in the prevention, diagnosis and treatment of cancer Originally recognized for these efforts in

Health - Pharmacology - 07.08.2013
Study of Afinitor in advanced liver cancer does not meet primary endpoint of overall survival
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib Study results do not impact use of Afinitor in othe

Health - Pharmacology - 01.08.2013
FDA expands age indication for Menveo , first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]
Meningococcal disease is a leading cause of bacterial meningitis, a rapidly progressing disease that can lead to death in otherwise healthy children , The highest rates of meningococcal disease in th

Health - Pharmacology - 26.07.2013
Novartis receives positive CHMP opinion for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
The CHMP has endorsed the use of Ilaris in patients aged 2 years and older who suffer from Systemic Juvenile Idiopathic Arthritis (SJIA) In Phase III studies, 84% of Ilaris-treated SJIA patients achi

Health - Pharmacology - 26.07.2013
Novartis first in class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) gains positive CHMP opinion for the treatment of COPD
QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain positive CHMP opinion Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standard of care QVA149 demonstrated significantly reduced rates of COPD exacerbations and improved health-relat

Health - Pharmacology - 24.07.2013
UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease, following JCVI interim recommendation on Novartis Bexsero vaccine
JCVI takes interim position to not recommend Bexsero for the routine immunization program, driven by evaluation based on cost-effectiveness assumptions The evaluation by JCVI was made prior to any pr

Pharmacology - Chemistry - 24.07.2013
A new method for clicking molecules together
A new method for clicking molecules together
Scientists at EPFL have developed a quick and simple method for connecting and assembling new molecules together, paving a new road for synthetic chemistry, material science, chemical biology, and even drug discovery. Thiols are sulfur-containing molecules found in most proteins of the human body. Characterized by their 'garlicky' smell, they also give coffee, sweat and the spray of skunks their unique odor.

Health - Pharmacology - 19.07.2013
Molecular validation of novel breast cancer therapeutic target
Under the leadership of Nancy Hynes, scientists from the Friedrich Miescher Institute for Biomedical Research have identified a potential novel target for breast cancer treatment. The scientists could show that breast cancer patients with high levels of the receptor tyrosine kinase Ret have a worse prognosis; and that blocking Ret not only decreases tumor growth but also impacts the potential of the cancer to spread throughout the body.

Business / Economics - Pharmacology - 17.07.2013
Novartis delivered growth across all divisions in second quarter (cc); raises guidance for full year 2013
Group net sales increased 1% (+3% cc ) versus year ago to USD 14.5 billion in second quarter, up 2% (+4% cc) to USD 28.5 billion in first half Core operating income was USD 3.8 b

Health - Pharmacology - 08.07.2013
Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world
License agreement advances a Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions More than 21 million cases of typhoid fever and five millio

Pharmacology - Health - 08.07.2013
Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel in head-to-head Phase III psoriasis study
FIXTURE trial of more than 1,300 moderate-to-severe plaque psoriasis patients showed superiority of secukinumab (AIN457) to Enbrel (etanercept) FIXTURE is a pivotal trial for registration; Regulatory submissions for secukinumab (AIN457), a therapy targeting IL-17A, are on tr ack for the second half of 2013 Basel, July 8, 2013 - Novartis announced today top-line results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to Enbrel * (etanercept), an anti-tumor necrosis factor (anti-TNF) therapy.

Pharmacology - Health - 05.07.2013
Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
Lucentis (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of only two injections with Lucentis treatment Myopic CNV, the growth of abnormal leaky blood vessels in the back of the eye in high myopia, often causes irreversible deteriora

Health - Pharmacology - 26.06.2013
Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic skin disease CSU[1]
Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU) Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four times the approved dose By Week 12 omalizumab eliminated or suppressed symptoms in more than half of patients who failed multiple therapies; benefit sustained during active tr

Pharmacology - Health - 24.06.2013
Sandoz launches Phase III clinical trial for biosimilar etanercept
Holzkirchen, Germany, June 24, 2013 - Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel ).

Pharmacology - Health - 21.06.2013
FDA grants Breakthrough Therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure
Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 years[1,2] RLX030 is the second Breakthrough Therapy designation by the FDA for Novartis investigational treatments, following LDK378 Basel, June 21 , 2013 - Novartis announced today that the US Food and Dr

Pharmacology - Health - 16.06.2013
Novartis drug Jakavi improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease
Jakavi reduced risk of death by 52% and sustained reductions in spleen size in new three-year COMFORT-II study data Analysis from a separate trial suggested that long-term treatment with Jakavi may stabilize or improve bone marrow fibrosis, a key marker of worsening disease Basel, June 16, 2013 - Novartis today announced results from a Phase III three-year follow-up study that showed Jakavi (ruxolitinib) demonstrated improved overall survival and sustained reductions in spleen size compared to conventional therapy.

Pharmacology - Life Sciences - 10.06.2013
Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis
Gilenya resulted in almost 50% more patients being free of MS disease activity after the switch from standard interferon treatment Annualized relapse rate reduced by >50% after 1 year for patients who switched from standard interferon treatment to Gilenya Reduced rate of brain volume loss sustained for up to 4.5 years in patients with active disease, despite prior treatment, who switched from interferon to Gilenya Basel, June 10 , 2013

Pharmacology - Health - 05.06.2013
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Gilenya improved the key measures: brain volume loss, MRI lesion activity, relapse rates and disability progression Switching to Gilenya from interferon increased the proportion of patients disease free after one year of treatment Gilenya resulted in sustained reduction of annualized relapse rate and the rate of brain volume loss in patients switched from interferon treatment Basel, June 5 , 2013 - New data will be presented at the 23 rd meeting

Pharmacology - Health - 03.06.2013
Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
Investigational compound LDK378 is a selective inhibitor of ALK , a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is underway Basel, June 3 , 2013 - Novartis today announced data on its investigat

Health - Pharmacology - 02.06.2013
Novartis pivotal Phase III trial shows Afinitor significantly delays tumor growth in HER2 positive advanced breast cancer
A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients First Phase III study sho

Health - Pharmacology - 31.05.2013
Lucentis receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections
Lucentis recommended for approval in EU to treat patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Lucentis superior to current standard of care and i

Health - Pharmacology - 29.05.2013
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
Latest Phase III research on Afinitor in HER2 positive advanced breast cancer Jakavi TM overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-threat

Pharmacology - Health - 29.05.2013
World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease
New campaign 'MS and:Our Story' announced today, providing MS community with platform to share experiences of life with MS Launch of new Novartis social media platforms to help generate dialogue, inf

Pharmacology - Health - 23.05.2013
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
INTERVAL study marks first assessment of the feasibility of setting and achieving individualized goals in this difficult-to-treat population of type 2 diabetes patients Study shows elderly type 2 diabetes patients three times more likely to reach an individualized HbA1c goal with no tolerability issues with vildagliptin than placebo Previous studies raised questions of uniform HbA1c targets for elderly type 2 diabetes patients, but no trials of

Pharmacology - Health - 21.05.2013
New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations
BLAZE study showed once-daily QVA149 significantly improved patient self-reported shortness of breath and lung function compared to placebo and tiotropium 18 mc g SPARK results showed that QVA149 significantly reduced rate of all exacerbations compared to glycopyrronium 50 mcg and open-label tiotropium 18 mcg , Pooled GLOW 1 and 2 data showed once-daily Seebri Breezhaler (glycopyrronium) significantly improved lung function in the first 4 hours

Health - Pharmacology - 21.05.2013
Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement
Breast cancer is the most common cancer in women worldwide, yet survey confirms many women living with advanced form of disease feel isolated , Three in four women surveyed say they actively seek out

Health - Pharmacology - 17.05.2013
Novartis drug Afinitor significantly extended time without disease progression in women with HER2 positive advanced breast cancer
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Everolimus plus trastuzumab and vinorel

Pharmacology - Health - 10.05.2013
Novartis drug Ilaris approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Ilaris (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection In Pha

Health - Pharmacology - 08.05.2013
Real-world data at ARVO highlight transformational outcomes seen with Lucentis , including lower injection frequency than in original clinical trials
UK real world study shows 59% reduction of legal blindness attributable to wet AMD since introduction of Lucentis with 9.7 injections spread over 5 years New one year REPAIR data shows visual acuity improvement of 14 letters with an average of 3.6 Lucentis injections in myopic CNV patients Largest Lucentis meta-analysis, over 10,000 patients, confirms well-established safety profile reported from extensive clinical trials and real

Health - Pharmacology - 26.04.2013
CHMP recommends conditional EU approval of Erivedge
CHMP recommends conditional EU approval of Roche's Erivedge for advanced basal cell carcinoma, a rare but potentially devastating form of skin cancer Roche announced today that the European Union's C

Pharmacology - Health - 25.04.2013
Novartis signs on to support Malaria No More’s Power of One campaign to stride towards a future without malaria
Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria Novartis will donate up to three million courses of pediatric antimalarial tr

Pharmacology - Business / Economics - 24.04.2013
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Sustained commitment to innovation resulted in eight key approvals in the EU and US and strong pipeline progress EMA approved Jetrea, Bexsero , a new indication for Ilaris and a line extension for Ex

Life Sciences - Pharmacology - 24.04.2013
Scientists identify important regulator for synapse stability and plasticity
Using the fruit fly as a model organism, neurobiologists from the Friedrich Miescher Institute for Biomedical Research have identified the L1-type CAM neuroglian as an important regulator for synapse growth, function and stability. They show that the interaction of neuroglian with ankyrin provides a regulatory module to locally control synaptic connectivity and function.

Health - Pharmacology - 23.04.2013
Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients
SPARK results published in Lancet Respiratory Medicine showed that dual bronchodilator QVA149 significantly reduced the rate of moderate or severe COPD exacerbations compared to glycopyrronium 50 mcg QVA149 significantly reduced the rate of all COPD exacerbations compared to open-label tiotropium 18 mcg and glycopyrronium Basel, April 23, 2013 - Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that inves

Health - Pharmacology - 19.04.2013
Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Simbrinza offers a wide range of treatm

Pharmacology - Health - 26.03.2013
Novartis confirms growing Gilenya clinical and real-world experience as number of patients treated increases to over 63,000
Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Gilenya is the only approved MS treatment shown to consistently decrease brain volume loss across studies with a significant effect seen as early as six months Low rate of brain volume loss with Gilenya sustained for up to four years in Phase III studies and for up to seven years in patients after completing a Phase II

Pharmacology - Health - 21.03.2013
New analysis shows Novartis drug Gilenya significantly reduced rate of brain volume loss across three large Phase III studies
Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS Gilenya is the first oral disease modifying treatment to show consistent effect on brain volume loss, an important indicator of disease progression Analysis of FREEDOMS II, a Phase III study, confirms Gilenya consistently reduces annualized relapse rates across disease activity, g

Health - Pharmacology - 18.03.2013
Alcon announces EU approval of Jetrea , first and only eye drug to treat sight-threatening vitreomacular traction and macular hole
Jetrea represents a breakthrough for patients with vitreomacular traction (VMT), a sight-threatening progressive condition, if left untreated One-time intravitreal injection of Jetrea has shown effic

Pharmacology - Health - 15.03.2013
Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
LDK378 is an investigational selective inhibitor of ALK , a target found in a variety of cancers including metastatic non-small cell lung cancer (NSCLC) Breakthrough Therapy designation is based on positive early data in patients with ALK+ NSCLC who have been previously treated with crizotinib First filing for LDK378 anticipated in early 2014 Basel, March 15, 2013 - Novartis announced today that its investigational compound LDK378 has received B

Pharmacology - Health - 13.03.2013
Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis
New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide Data from over 500 patients treated for up to four years reinforces the known, manageable safety profile of once-daily oral Gilenya Progress reported with Novartis portfolio in studies of patients with primary-progressive MS and secondary-progressive MS, forms of the condition where treatment options

Health - Pharmacology - 01.03.2013
Novartis receives EU approval for Ilaris in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments
Ilaris is the first biologic approved in the EU for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection The intense inflammatory response

Health - Pharmacology - 28.02.2013
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
RHD has been eliminated in most developed nations, but sub-Saharan Africa studies show at least 2-3% of school-age children suffer from this often fatal disease Collaboration between Novartis physici

This site uses cookies and analysis tools to improve the usability of the site. More information. |